NCT07852546
Cardioprotection Effect of Linagliptin
Not Yet Recruiting · Phase 3 · Tanta University · registry updated 2026-10-15
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
1\. Background and Rationale Breast cancer is one of the most common malignancies affecting women worldwide and represents a major health burden in Egypt. Anthracyclines, particularly doxorubicin, remain an important component of several breast cancer chemotherapy regimens. However, their clinical utility is limited by the potential development of anthracycline-induced cardiotoxicity. Doxorubicin-induced cardiac injury is multifactorial and involves oxidative stress, mitochondrial dysfunction, disturbances in myocardial energy metabolism, apoptosis, inflammation, and progressive myocardial structural damage. Cardiac injury may initially occur without symptoms or an obvious reduction in left ventricular ejection fraction (LVEF). Consequently, identification of early myocardial injury is important because intervention before clinically apparent heart failure may potentially reduce progression to overt cardiac dysfunction.
Inclusion
- Female patients aged ≥18 years.
- Egyptian nationality.
- Histologically confirmed breast cancer.
- Planned treatment with a doxorubicin-containing chemotherapy regimen.
- Expected cumulative doxorubicin dose of approximately ≥240 mg/m², or another prespecified protocol threshold.
- Baseline LVEF ≥53%.
Exclusion
- Previous exposure to anthracyclines.
- Known heart failure.
- Baseline LVEF \<53%.
- Previous myocardial infarction or significant coronary artery disease.
- Significant valvular heart disease.
- Clinically significant arrhythmia.